The information in this section is intended for visitors outside the United States.
Bristol-Myers Squibb and Gilead Sciences Establish U.S. Joint Venture to Develop and Commercialize Fixed-Dose Combination of Three HIV Medicines
Gilead Sciences to Present at the Harris Nesbitt 4th Annual Investor Conference on Wednesday, December 8th; Webcast Available Through Gilead Corporate Website
Gilead Sciences to Present at the Lazard 1st Annual Life Sciences Conference on Wednesday, December 1st; Webcast Available Through Gilead Corporate Website
Gilead and Achillion Announce Collaboration for the Development and Commercialization of Achillion's Hepatitis C Compounds
Gilead Sciences Announces Completion of Redemption of 2% Convertible Senior Notes
Gilead Sciences to Present at the Punk, Ziegel & Company's Investor Symposium on Monday, November 22nd; Webcast Available Through Gilead Corporate Website
European CHMP Gives Positive Opinion on Gilead's Truvada as Part of Combination HIV Therapy
Gilead Sciences to Present at the Credit Suisse First Boston Annual Healthcare Conference on Thursday, November 18th; Webcast Available Through Gilead Corporate Website
Gilead Announces Long-Term Safety and Efficacy Data, Through 144 Weeks, for Hepsera in Patients With Chronic Hepatitis B
Interim 24-Week Data from Study 934 Comparing a Regimen of Viread and Emtriva Versus Combivir, Both in Combination with Efavirenz, in Patients with HIV Presented at 44th ICAAC
Gilead Discontinues Development of GS 9005 and GS 7340; Company Continues Commitment to Research Efforts in HIV
Gilead Sciences Announces Third Quarter 2004 Financial Results
Gilead Sciences to Release Third Quarter 2004 Financial Results on Thursday, October 21, 2004; Conference Call and Webcast to Follow
Gilead Sciences Calls for Redemption of Convertible Subordinated Notes
Gilead and Genelabs Announce Research Collaboration and License Agreement for the Development of Genelabs' Novel Hepatitis C Compounds
CORRECTING and REPLACING Gilead Sciences Announces Acceptance of Study 934 Late Breaker Abstract at 44th Annual ICAAC in Washington, DC
Gilead Sciences to Present at the UBS Global Life Sciences Conference on Monday, September 27th; Webcast Available Through Gilead Corporate Website
Kevin Young Joins Gilead Sciences as Executive Vice President, Commercial Operations
Gilead Sciences to Present at the BioCentury and Thomson Financial Newsmakers in the Biotech Industry Conference on Thursday, September 9th
Gilead Sciences to Present at the Thomas Weisel Partners Healthcare Tailwinds 2004 Conference on Wednesday, September 8th
Gilead Announces Preliminary 24-Week Data from Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Efavirenz In Patients With HIV
Gilead Expands Initiatives Providing Access to New HIV Therapy Truvada in United States and Abroad
Gilead Sciences' Board Member Establishes Rule 10b5-1 Stock Trading Plan
U.S. FDA Approves Gilead's Truvada, a One-Tablet, Once-a-Day Fixed-Dose Co-Formulation of Viread and Emtriva as Part of HIV Combination Therapy
Gilead Sciences Announces Second Quarter 2004 Financial Results
Gilead Board of Directors Approves Two-for-One Stock Split
Gilead Sciences to Release Second Quarter 2004 Financial Results on Thursday, July 29, 2004; Conference Call and Webcast to Follow
Gilead Signs Inventory Management Agreements with the Three Major U.S. Wholesalers
Pivotal Studies of Gilead's Viread and Emtriva Published in Special International Aids Conference Issue of Journal of the American Medical Association
Gilead Reduces Price of Viread in the Developing World by 37 Percent; Anti-HIV Medication Available to 68 Resource-Limited Countries Through the Gilead Access Program
Gilead Sciences to be Added to S&P 500 Index
Gilead Sciences to Present at the 25th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 8th; Webcast Available Through Gilead Corporate Website
CORRECTING and REPLACING Gilead Sciences to Present at the Banc of America Securities 2004 Healthcare Conference on Friday, May 21st
Gilead Sciences to Present at the Banc of America Securities 2004 Healthcare Conference on Friday, May 21st; Webcast Available Through Gilead Corporate Website
Bristol-Myers Squibb, Gilead Sciences and Merck & Co., Inc. Announce Plans to Develop Fixed-Dose Combination of Three HIV Medicines
Gilead Sciences Announces New Commercial Structure and Changes to Senior Management Team; Expansion and Reorganization of Commercial Group to Support Anticipated Growth
Gilead Sciences Announces First Quarter 2004 Financial Results; Total Revenues of $309 Million, Up 87 Percent over First Quarter 2003
Gilead Sciences to Release First Quarter 2004 Financial Results on Thursday, April 22, 2004; Conference Call and Webcast to Follow
New Data Support Hepsera's Long-Term Efficacy against Chronic Hepatitis B
Nicholas G. Moore Joins Gilead Sciences Board of Directors
Gilead Submits Applications to U.S. and European Regulatory Authorities for Fixed Dose Co-Formulation of Viread and Emtriva
Gilead Sciences to Present at the 24th Annual SG Cowen Healthcare Conference on Tuesday, March 9th; Webcast Available Through Gilead Corporate Website
Gilead Sciences to Present at the 7th Annual Lehman Brothers Global Healthcare Conference on Friday, March 5th; Webcast Available Through Gilead Corporate Website
Gilead Sciences to Present at 2004 BIO CEO & Investor Conference; Webcast Available Through Gilead Corporate Website
Gilead Announces Data from Landmark Three-Year Clinical Trial of Viread; 144-Week Data Highlight Viread Efficacy, Safety and Side Effect Profile
Gilead Sciences Announces Fourth Quarter and Full Year 2003 Financial Results
Gilead, Emory University and the University of Georgia Research Foundation End Licensing Agreement for Amdoxovir, Investigational Agent for HIV
Gilead Sciences to Release Fourth Quarter and Year-End 2003 Financial Results on Thursday, January 29, 2004; Conference Call and Webcast to Follow
Gilead Files Investigational New Drug Application for Its Novel Protease Inhibitor; Anti-HIV Drug Developed Using Gilead's Proprietary Prodrug Technology
Gilead Sciences to Present at the 22nd Annual JPMorgan Healthcare Conference on Monday, January 12th; Webcast Available Through Gilead Corporate Website